Connor Iapoce

BIOS-ROP study results indicate the bevacizumab biosimilar monotherapy leads to complete ROP regression in almost two-third of the eyes after 24 weeks of treatment.

The FDA grants the company agreement under a Special Protocol Assessment to evaluate TRS01 ophthalmic solution for the treatment of non-infectious uveitis, including uveitic glaucoma.

Prescribing phosphodiesterase type 5 inhibitors and nitrates together may increase the risk of morbidity and mortality for patients over time.

Autonomous AI increases diabetic eye exam completion rates in a diverse population of youth with diabetes.

A local corticosteroid burst followed by 0.18 mg FAi may be a useful adjuvant for the treatment of noninfectious uveitis, but not sufficient as solo therapy.

Moderate-to-severe anemia decreased the likelihood of a favorable outcome after mechanical thrombectomy compared with no anemia.

The novel topical dry eye disease candidate achieved a statistically significant ≥10-mm increase in unanesthetized Schirmer’s score at Day 14.

Two-year XTEND trial data shows proactive aflibercept led to meaningful functional and anatomic improvements that were maintained across the study period.

Patients with lung cancer treated with EGFR inhibitors may experience a greater risk for keratitis, particularly with afatinib treatment.

A meta-analysis of RCTs revealed significant advantages with faricimab treatment in improving CST and reducing injection frequency among eyes with AMD or DME.

Positive interim data from the TEASE-3 clinical trial show gildeuretinol slows the progression of Stargardt Disease for up to six years.

A meta-analysis of 14 randomized trials suggests a beneficial effect of intravenous iron on cardiovascular mortality and heart failure readmissions.

A multidisciplinary panel assembled by the Society for Cardiovascular Angiography & Interventions examined and supported the role of intravascular ultrasounds in lower extremity revascularization procedures.

Randomized trial data shows colchicine administered following catheter ablation did not reduce atrial arrhythmia recurrence or associated clinical events.

Results of the 76-week trial suggest that a treat-and-extend aflibercept regimen yields similar functional and anatomic outcomes as fixed dosing every 8 weeks among patients with nAMD.

Eyes with DED showed a correlation between the severity of ocular symptoms, obtained using dry eye and pain questionnaires, and all aspects of sleep quality.

A new study identified T1D as a risk factor associated with nearly all subtypes of CHD, whereas overweight was associated only with certain defect types.

For the first time, the FDA has approved a plan allowing Florida to import certain, cheaper prescription drugs from Canada.

A new cohort study in China reports suggests the structure of green space decreased the relative risk of myopia among school-aged children.

A retrospective cohort study showed patients with Alzheimer disease treated with AChEIs had a slightly lower risk of incident AMD compared with untreated patients.

A case-control analysis shows the majority of autoimmune diseases demonstrate no effect on the development of new-onset age-related macular degeneration.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our December 2023 month-in-review features a recap of This Year in Medicine, the latest updates to the ophthalmic pipeline, and the newest episode of our KOL-led podcast series.

Over 8 years of follow-up, patients with high myopia and a rapid progression trajectory had a nearly 7 times higher risk of developing pathological macular degeneration.

Among more than 3 million adults, a team of investigators observed an increased risk of both falls and fractures among people with cataract, age-related macular degeneration, and glaucoma.

Firework-related eye injuries were more likely in areas where fireworks were legal, compared to banned areas.

Reports of eye infection and enucleation related to OTC eye drops concerned the eye care community in 2023 and drove increased vigilance towards ensuring safer ophthalmic products.

A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents.

Cross-sectional data show an increasing incidence of syphilitic uveitis–related hospitalizations in the US between 2010 and 2019.

Patients with retinal diseases found intravitreal anti-VEGF therapy and disease management challenging, but most expressed high levels of satisfaction with their treatment.

Based on the special protocol assessment submission, the company expects to begin the non-inferiority trial for the ophthalmic bevacizumab in the first quarter of 2024.